Target Name: VTN
NCBI ID: G7448
Review Report on VTN Target / Biomarker Content of Review Report on VTN Target / Biomarker
VTN
Other Name(s): somatomedin B | Vitronectin V10 subunit | Complement S-protein | S-protein | Vitronectin (serum spreading factor, somatomedin B, complement S-protein) | Serum-spreading factor | Vitronectin V65 subunit | epibolin | VN | serum spreading factor | Somatomedin B | VTNC_HUMAN | Vitronectin | complement S-protein | vitronectin | Somatomedin-B | Epibolin | V75 | VNT | Serum spreading factor

VTN: A Protein Target for Therapeutic Applications

VTN, or somatomedin B, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a key regulator of cell growth and differentiation, and has been shown to play a role in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, VTN has emerged as a promising drug target for a range of therapeutic applications.

The protein VTN is composed of 256 amino acids and has a calculated molecular mass of 31.1 kDa. It is expressed in a variety of tissues, including the brain, heart, and skeletal muscles, and is involved in a number of important cellular processes, including cell growth, differentiation, and signaling.

One of the most significant functions of VTN is its role as a regulator of cell growth and differentiation. This protein is involved in the regulation of cell proliferation, and has been shown to play a role in the regulation of neural stem cell proliferation and differentiation. In addition, VTN is also involved in the regulation of cell differentiation, and has been shown to play a role in the regulation of muscle cell differentiation.

In addition to its role in cell growth and differentiation, VTN is also involved in a number of other important cellular processes, including cell signaling and inflammation. This protein is involved in a number of signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. In addition, VTN is also involved in the regulation of inflammation, and has been shown to play a role in the regulation of immune cell function.

Due to its involvement in a number of important cellular processes, VTN has been shown to be a promising drug target for a range of therapeutic applications. In addition to its potential use as a treatment for a variety of neurological and psychiatric disorders, VTN has also been shown to have potential applications in a number of other fields, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, VTN is a protein that is expressed in various tissues throughout the body, and is involved in a number of important cellular processes, including cell growth, differentiation, and signaling. As a result, VTN has emerged as a promising drug target for a range of therapeutic applications. Further research is needed to fully understand the role of VTN in disease, and to develop safe and effective treatments.

Protein Name: Vitronectin

Functions: Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway

The "VTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54